Terms: = Lung cancer AND FCGR2B, FCGR2, 2213, ENSG00000072694, CD32, CD32B, P31994, IGFR2, FCG2 AND Prognosis
1 results:
1. High levels of PD-L1 on platelets of NSCLC patients contributes to the pharmacological activity of Atezolizumab.
Colarusso C; Falanga A; Terlizzi M; De Rosa I; Somma P; Sommella EM; Caponigro V; Panico L; Salviati E; Campiglia P; Salatiello G; Tramontano T; Maiolino P; Pinto A; Sorrentino R
Biomed Pharmacother; 2023 Dec; 168():115709. PubMed ID: 37857253
[TBL] [Abstract] [Full Text] [Related]
